Developing novel therapeutics for serious rare conditions
Therachon is a global biotechnology company committed to making a difference in the lives of patients living with serious rare conditions.
We are assembling a growing best-in-disease pipeline that shows great promise in both Achondroplasia and Short Bowel Syndrome.
We are headquartered in Basel, Switzerland, with research labs in Nice, France and business operations in the New York area.
Therachon to Present Data from Ongoing Phase II Study of Apraglutide for Short Bowel Syndrome (SBS) at Digestive Disease Week
Data to be presented from Phase II study of two patients with short bowel syndrome in an ongoing study of apraglutide BASEL, Switzerland, May 17, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biopharmaceutical…
Pfizer Acquires Clinical-Stage Biotech Therachon
Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today…
Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
– Results establish favorable safety profile and show the potential for efficacy with once-weekly dosing of a next generation GLP-2 analog – In head-to-head rat studies, apraglutide displayed a longer…